Indeed, though our data suggest that HERC1 plausibly plays a role as oncosuppressor in the majority of myeloid malignancies (e.g., AML, CML and PMF) by now we cannot rule out that in those ET calreticulin mutated it might display tumor-promoting properties, thus exerting different properties depending on the context. This evidence concerns the gene HERC1 and neoplasm.